PYRIMIDINE DERIVATIVE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME AS EFFECTIVE COMPONENT

• Main Authors: YUN, Jiyeon, DUGGIRALA, Krishna Babu, LEE, Kwangho, JUNG, Myoung Eun, CHOI, Gildon, PARK, Chae Won, CHAE, Chong Hak, CHO, Byoung Chul
• Format: Patent
• Language: English; French; Korean
• Published: 22.04.2021
• Subjects: CHEMISTRY; FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

The present invention relates to a pyrimidine derivative, a method of preparing same, and a pharmaceutical composition for preventing or treating cancer, comprising the pyrimidine derivative as an effective component, wherein the derivative exhibits a relatively weak inhibitory effect on EGFR activity with respect to wild-type EGFR while exhibiting a high inhibitory effect with respect to EGFR mutations, and thus can be effectively used for the treatment of cancer with EGFR mutations. La présente invention concerne un dérivé de pyrimidine, un procédé de préparation de celui-ci, et une composition pharmaceutique pour prévenir ou traiter le cancer, comprenant le dérivé de pyrimidine en tant que composant actif, le dérivé présentant un effet inhibiteur relativement faible sur l'activité de l'EGFR par rapport à l'EGFR de type sauvage tout en présentant un effet inhibiteur élevé vis-à-vis des mutations de l'EGFR, et peut ainsi être utilisé de manière efficace pour le traitement du cancer ayant des mutations de l'EGFR. 본 발명은 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물에 관한 것으로, 상기 유도체는 야생형 EGFR에 대하여 상대적으로 약한 EGFR 활성억제효과를 나타내면서, EGFR 돌연변이에 대하여 높은 억제능을 나타내므로, EGFR 돌연변이가 발생된 암의 치료에 유용하게 사용될 수 있다.